{"address1": "1901 West 47th Place", "city": "Kansas City", "state": "KS", "zip": "66205", "country": "United States", "phone": "913 942 2300", "website": "https://www.cingulate.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Raul R. Silva M.D.", "age": 66, "title": "Co-Founder, Executive VP & Chief Science Officer", "yearBorn": 1958, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Thomas  Dalton", "title": "Vice President of Investor & Public Relations", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.059, "open": 0.0598, "dayLow": 0.05, "dayHigh": 0.06, "regularMarketPreviousClose": 0.059, "regularMarketOpen": 0.0598, "regularMarketDayLow": 0.05, "regularMarketDayHigh": 0.06, "beta": -0.844, "volume": 7654, "regularMarketVolume": 7654, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 0.05, "fiftyTwoWeekHigh": 0.06, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 3203367, "bookValue": 3.954, "priceToBook": 0.012670713, "netIncomeToCommon": -15545737, "trailingEps": -1.732, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.0501, "recommendationKey": "none", "totalCash": 10040149, "totalCashPerShare": 3.126, "ebitda": -14987922, "totalDebt": 234174, "debtToEquity": 1.945, "returnOnEquity": -6.016, "grossProfits": -9445265, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CINGW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketTime": 1743537600, "marketState": "PRE", "regularMarketChangePercent": -15.084748, "regularMarketPrice": 0.0501, "shortName": "Cingulate Inc. Warrants", "longName": "Cingulate Inc.", "exchange": "NCM", "messageBoardId": "finmb_1674914781", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketChange": -0.008900002, "regularMarketDayRange": "0.05 - 0.06", "fullExchangeName": "NasdaqCM", "fiftyTwoWeekLowChange": 9.999797e-05, "fiftyTwoWeekLowChangePercent": 0.0019999593, "fiftyTwoWeekRange": "0.05 - 0.06", "fiftyTwoWeekHighChange": -0.0099, "fiftyTwoWeekHighChangePercent": -0.165, "epsTrailingTwelveMonths": -1.732, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-12-08", "cryptoTradeable": false, "hasPrePostMarketData": true, "displayName": "Cingulate", "trailingPegRatio": null}